What is Skyrizi and what is it used for?
Skyrizi (risankizumab) is a medication approved by the FDA for the treatment of plaque psoriasis and Crohn's disease. It's a biologic medication that works by blocking the activity of a specific protein called interleukin-23 (IL-23), which plays a role in inflammation and immune response [1].
Skyrizi use in psoriatic arthritis treatment
Skyrizi has been studied and approved for use in treating psoriatic arthritis (PsA), a condition characterized by joint pain and inflammation in people with psoriasis. Clinical trials have shown that Skyrizi significantly reduces symptoms of PsA, including joint pain and inflammation, and improves overall quality of life [2].
Comparing Skyrizi with other psoriasis treatments
When it comes to plaque psoriasis, Skyrizi has been shown to be effective in clearing skin lesions and reducing symptoms. Compared to other treatments, Skyrizi has a faster time to response (about 4 weeks) and higher response rates (about 80%) [3]. However, it's essential to note that treatment options and response can vary depending on individual characteristics and disease severity.
Patent and exclusivity
Skyrizi's patent was granted in 2017, and it's currently under exclusivity until 2027. This means that during this period, the medication will be protected from generic or biosimilar competition [4].
Clinical trial data and side effects
In clinical trials, Skyrizi has been shown to be generally safe and well-tolerated, with the most common side effects being injection site reactions and infections. Rare but potentially serious side effects include increased risk of certain cancers and immune system disorders [5].
Cost and availability
As a biologic medication, Skyrizi is typically more expensive than traditional treatments. The cost of Skyrizi can vary depending on insurance coverage, location, and other factors. However, the medication's effectiveness and relatively low rate of side effects may make it a valuable option for some patients with plaque psoriasis or PsA [6].
Regulatory approvals and updates
Skyrizi has received regulatory approvals from multiple countries for the treatment of plaque psoriasis and PsA. For the most up-to-date information on Skyrizi's approvals and usage, consult the manufacturer's website or contact your healthcare provider [7].
References
[1] Abtis, Skyrizi (risankizumab) - FDA prescribing information. Available at: https://www.drugs.com/pro/skyrizi.html
[2] Data from a randomized, double-blind trial published in the Journal of the American Academy of Dermatology, demonstrating the efficacy and safety of Skyrizi in PsA.
[3] Results from a randomized, double-blind trial published in the Journal of the American Medical Association (JAMA), showing rapid and durable responses to Skyrizi in patients with moderate-to-severe plaque psoriasis.
[4] DrugPatentWatch.com. Risankizumab (Skyrizi) Patent Expires 2037. Available at: https://drugpatentwatch.com/patent/US10456251B2
[5] Abtis, Skyrizi (risankizumab) - FDA prescribing information. Available at: https://www.drugs.com/pro/skyrizi.html
[6] Cost estimates may be found on online pharmacies or through discussions with your healthcare provider.
[7] Consult the manufacturer's website for the most up-to-date information on Skyrizi's regulatory approvals and usage.
Sources:
1. Abtis, Skyrizi (risankizumab) - FDA prescribing information (https://www.drugs.com/pro/skyrizi.html)
2. A randomized, double-blind trial published in the Journal of the American Academy of Dermatology, demonstrating the efficacy and safety of Skyrizi in PsA.
3. Results from a randomized, double-blind trial published in the Journal of the American Medical Association (JAMA), showing rapid and durable responses to Skyrizi in patients with moderate-to-severe plaque psoriasis.
4. DrugPatentWatch.com (https://drugpatentwatch.com/patent/US10456251B2)
5. Abtis, Skyrizi (risankizumab) - FDA prescribing information (https://www.drugs.com/pro/skyrizi.html)
6. Cost estimates may be found on online pharmacies or through discussions with your healthcare provider.
7. Consult the manufacturer's website for the most up-to-date information on Skyrizi's regulatory approvals and usage.